Initiation of ARNi and SGLT2i in Patients With HFrEF (INITIATE)
Heart Failure With Reduced Ejection Fraction
About this trial
This is an interventional treatment trial for Heart Failure With Reduced Ejection Fraction
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Heart failure symptoms (NYHA II, III or IV) Left ventricle ejection fraction ≤ 49% (assessed by transthoracic echocardiogram) Glomerular filtration rate ≥ 25 ml/min/1.73m2 (CKD-EPI formula) Serum potassium (K+) ≤ 5.4 mmol/L Systolic blood pressure ≥ 100 mmHg Not treated with ARNi nor with SGLT2i within the previous month (30 days before inclusion, except if initiated 5 days before randomization) If female, she must not be a woman of childbearing potential. That is, she must be: Surgically sterilized (e.g., underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy) Clinically diagnosed infertile In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause If female patient of childbearing potential, she must have a negative serum pregnancy test at Visit 1 (Day 0) and must agree to consistently and correctly use (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception: Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject) Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) Intrauterine device Intrauterine hormone-releasing system Bilateral tubal occlusion Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner Exclusion Criteria: Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) Participation in another clinical study with an investigational product during the last month Unwilling to sign inform consent Patients with a known hypersensitivity or intolerance to ARNi or SGLT2i or any of the excipients of the products Hospitalization due to non-cardiovascular causes, surgical procedure, coronary, cerebral or peripheral vascular events or sepsis in the prior month Cancer (life limiting with an estimated life expectancy of less than 2 years based on investigator's judgement) Previously confirmed cardiac amyloidosis History of angioedema Implantable cardioverter-defibrillators or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device in the 3 months following screening Female patients currently pregnant (confirmed by a positive pregnancy test) or intent to become pregnant or breast feeding Severe valvulopathy according to the echocardiogram report Previous history of ketoacidosis due to SGLT2i
Sites / Locations
- Centro Hospitalar Universitário de Santo AntónioRecruiting
- Centro Hospitalar Universitário São JoãoRecruiting
- Faculty of Medicine (FMUP)Recruiting
- Centro Hospitalar Vila Nova de Gaia/EspinhoRecruiting
- Unidade Local de Saúde de Matosinhos - Hospital Pedro HispanoRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Simultaneous initiation
Sequential initiation
ARNi (initial dose 24/26mg b.i.d. or 49/51mg b.i.d. titrated to 97/103mg b.i.d. preferably in the first 3-6 weeks, up to 3 months of follow-up) and SGLT2i (10mg q.d.) on the same day or within ± 5 days.
Initial (at randomization day) SGLT2i prescription (either empagliflozin or dapagliflozin, 10 mg q.d.) followed by an ARNi initiated between weeks 4 and 12 after randomization (sacubitril/valsartan at an initial dose of 24/26mg b.i.d. or 49/51mg b.i.d., and titrated to 97/103mg b.i.d. if tolerated, according to assistant physician decision)